Zydus Cadila is focusing on generics that are difficult to develop and manufacture, as well as on specialty brands, in the US as the Indian company aims to improve its profit margins. The group is also seeking inorganic growth through “selective mergers and acquisitions” in the US, India, and its Emerging Markets region in Asia and Africa.
Citing Iqvia data for the 12 months ended January 2018, the Indian company said it ranked ninth among US generics...